No Data
Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Arrives In U.S.
Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Clearmind Medicine To Develop Novel Intranasal Formulation With Polyrizon
Clearmind Medicine Announced That It Has Signed A Non-binding Letter Of Intent With Polyrizon To Develop A Novel Intranasal Formulation For Its Psychedelic-based Treatment Applications
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
Clearmind Begins Human Trials for Potential Psychedelic Treatment for Alcohol Abuse Patients
